CHEK1 and cancer: Prexasertib (LY2603618) is a dual Chk1/2 ATP‐competitive inhibitor induced mitotic catastrophe and apoptosis in cancer cells and showed synergistic effect in combination with both cisplatin and PARPi in in vivo models.247, 248